Previous 10 | Next 10 |
2023-08-08 11:26:07 ET Ironwood Pharmaceuticals, Inc. (IRWD) Q2 2023 Earnings Call Transcript August 08, 2023 08:30 AM ET Company Participants Matt Roache - Director of Investor Relations Tom McCourt - Chief Executive Officer Sravan Emany - Chief Financial Office...
2023-08-08 07:25:44 ET Ironwood Pharmaceuticals press release ( NASDAQ: IRWD ): Q2 Non-GAAP EPS of -$6.71 misses by $6.96 . Revenue of $107.38M (+10.4% Y/Y) beats by $3.66M . Ironwood is increasing its 2023 U.S. LINZESS net sales and total revenue growth guidan...
– LINZESS (Iinaclotide) EUTRx prescription demand growth increased 9% year-over-year; LINZESS U.S. net sales of $270 million, an increase of 9% year-over-year – – Expands clinical utility of LINZESS with FDA approval for pediatric patients ages 6-17 years-old sufferin...
2023-08-07 14:36:26 ET Ironwood Pharmaceuticals ( NASDAQ: IRWD ) is scheduled to announce Q2 earnings results on Tuesday, August 8th, before market open. The consensus EPS Estimate is $0.25 (+19.0% Y/Y) and the consensus Revenue Estimate is $103.72M (+6.7% Y/Y). Over t...
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its second quarter 2023 investor update conference call and webcast at 8:30 a.m. Eastern Time on Tuesday, August 8, 2023. Individuals interested in participating in the call should dial (888) 330-2384 (U.S. and Canada) o...
2023-07-19 11:00:00 ET Summary Pharmaceuticals/biotechnology is the most attractive subsector regarding both value and quality scores. Healthcare equipment is the most overpriced healthcare industry. Fast facts on iShares U.S. Healthcare ETF. 10 healthcare stocks cheaper t...
Ironwood Pharmaceuticals, Inc. (“Ironwood”) (Nasdaq: IRWD), a GI-focused healthcare company, and VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a global clinical-stage biopharmaceutical company pioneering novel, transformational treatments for severe rare gastroint...
2023-06-19 05:16:46 ET Summary Pharma/biotechnology and healthcare providers are slightly undervalued relative to 11-year averages. Healthcare equipment is the most overvalued subsector. Fast facts on PBE, a genomics ETF. 10 healthcare stocks cheaper than their peers in Ju...
Ironwood Pharmaceuticals, Inc. (“Ironwood”) (Nasdaq: IRWD), a GI-focused healthcare company, and VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a global clinical-stage biopharmaceutical company pioneering novel, transformational treatments for severe rare gastroint...
2023-06-12 17:53:16 ET The US Food and Drug Administration has expanded its approval of Ironwood Pharmaceuticals' ( NASDAQ: IRWD ) drug Linzess to include the treatment of functional constipation in children and teens. Linzess was already approved to treat adults with irritable ...
News, Short Squeeze, Breakout and More Instantly...
Ironwood Pharmaceuticals Inc. Company Name:
IRWD Stock Symbol:
NASDAQ Market:
Ironwood Pharmaceuticals Inc. Website:
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its second quarter 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, August 8, 2024. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) ...
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Sravan Emany, Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 9:00 a.m. ET at the Marriott Marquis in New York City. A live webcast of I...
2024-05-22 07:30:10 ET Wells Fargo analyst issues OVERWEIGHT recommendation for IRWD on May 22, 2024 05:13AM ET. The previous analyst recommendation was Overweight. IRWD was trading at $6.78 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...